Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 12, 2010, Pages 6906-

  Sharma, Rajesh K ^a   Balaiya, Sankarathi ^a   Chalam, Kakarla V ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EPITOPE; IMMUNOGLOBULIN G1; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL NEOPLASM; EYE CANCER; EYE MELANOMA; LETTER; MELANOMA; METASTASIS INHIBITION; MICROMETASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; APOPTOSIS; CASPASE 3; CELL PROLIFERATION; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; MELANOMA, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955969384     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.10-6275     Document Type: Letter

References (2)

1. Yang H, Jager MJ, Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis. Sci. 2010;51(6):2835-2842.
2. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333:328-335.